Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.0 - $1.53 $16,054 - $24,562
16,054 New
16,054 $24,000
Q2 2023

Aug 09, 2023

BUY
$2.15 - $3.49 $128,677 - $208,876
59,850 Added 178.59%
93,363 $213,000
Q1 2023

May 12, 2023

BUY
$1.99 - $2.68 $18,485 - $24,894
9,289 Added 38.35%
33,513 $81,000
Q4 2022

Feb 09, 2023

SELL
$1.8 - $2.56 $189,086 - $268,922
-105,048 Reduced 81.26%
24,224 $46,000
Q3 2022

Nov 09, 2022

BUY
$1.94 - $3.43 $67,263 - $118,924
34,672 Added 36.65%
129,272 $310,000
Q2 2022

Aug 11, 2022

BUY
$1.31 - $2.69 $19,174 - $39,373
14,637 Added 18.3%
94,600 $176,000
Q1 2022

May 12, 2022

SELL
$1.95 - $3.89 $106,694 - $212,841
-54,715 Reduced 40.63%
79,963 $167,000
Q4 2021

Feb 11, 2022

BUY
$3.81 - $6.16 $450,742 - $728,758
118,305 Added 722.56%
134,678 $531,000
Q3 2021

Nov 12, 2021

SELL
$3.38 - $5.35 $68,309 - $108,123
-20,210 Reduced 55.24%
16,373 $79,000
Q2 2021

Aug 10, 2021

BUY
$4.12 - $5.87 $150,721 - $214,742
36,583 New
36,583 $168,000
Q1 2021

May 12, 2021

SELL
$3.45 - $9.09 $127,957 - $337,139
-37,089 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$1.05 - $3.67 $36,853 - $128,813
35,099 Added 1763.77%
37,089 $127,000
Q3 2020

Nov 12, 2020

BUY
$1.44 - $2.1 $2,865 - $4,179
1,990 New
1,990 $3,000
Q2 2020

Aug 13, 2020

SELL
$1.75 - $2.3 $16,325 - $21,456
-9,329 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$1.8 - $4.28 $16,792 - $39,928
9,329 New
9,329 $18,000
Q1 2019

May 13, 2019

SELL
$4.36 - $7.94 $12,142 - $22,112
-2,785 Closed
0 $0
Q4 2018

Feb 06, 2019

BUY
$6.15 - $10.51 $17,127 - $29,270
2,785 New
2,785 $18,000
Q4 2017

Feb 09, 2018

SELL
$8.77 - $12.28 $614,706 - $860,729
-70,092 Closed
0 $0
Q3 2017

Nov 15, 2017

BUY
$12.17 - $16.3 $853,019 - $1.14 Million
70,092
70,092 $861,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $302M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.